The development of tumor cell resistance to natural product anti-cancer drugs is widely recognized as a major limiting factor in patient responsiveness to chemotherapy programs. A common mechanism for the acquisition of tumor cell multi-drug resistance (MDR) is through increased activity of P-glycoprotein, which acts as an energy-dependent drug efflux pump. It is therefore likely that the identification of compounds which circumvent this mechanism of resistance will enhance the successfulness of cancer chemotherapy. We have established a program to identify such anti-MDR compounds. In a collection of extracts from different species of cyanobacteria, two classes of compounds which circumvent P-glycoprotein-mediated MDR have been identified. Firstly, certain members of a family of macrolides called scytophycins have been found to demonstrate equivalent cytotoxicities toward normal cells and MDR cells, i.e. they do not appear to be transported by P-glycoprotein. Secondly, a family of novel porphyrins which chemosensitize P-MDR cells has been isolated. We have also recently found that closely structurally related cytochalasins interact very differently with P-glycoprotein. Studies conducted under the present proposal will characterize the biochemical and pharmacological anti-MDR properties of these natural products. The effects of each chemosensitizing compound on P-glycoprotein activity (drug binding and transport), P-glycoprotein expression (both protein and mRNA) and MDR cell chemosensitivity will be established. Cellular responses to longterm exposure to these agents will be examined. Additional active compounds in these extracts are currently being isolated, and their pharmacological properties will be similarly characterized. These studies may lead to the identification of new compounds which either inhibit P-glycoprotein activity or which elude the Pglycoprotein mechanism of resistance. Such compounds may allow new approaches to the chemotherapy of drug-resistant cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA064983-02
Application #
2107745
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1994-02-01
Project End
1997-01-31
Budget Start
1995-02-01
Budget End
1996-01-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Lee, Brian D; French, Kevin J; Zhuang, Yan et al. (2003) Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol Res 14:49-60
Lawrence, D S; Copper, J E; Smith, C D (2001) Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J Med Chem 44:594-601
Xia, Z; Smith, C D (2001) Total synthesis of dendroamide A, a novel cyclic peptide that reverses multiple drug resistance. J Org Chem 66:3459-66
Smith, C D; Myers, C B; Zilfou, J T et al. (2000) Indoloquinoxaline compounds that selectively antagonize P-glycoprotein. Oncol Res 12:219-29
Dinh, T Q; Smith, C D; Du, X et al. (1998) Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of hapalosin. J Med Chem 41:981-7
Zhang, X; Smith, C D (1996) Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol Pharmacol 49:288-94
Ogino, J; Moore, R E; Patterson, G M et al. (1996) Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. J Nat Prod 59:581-6
Smith, C D; Zilfou, J T; Stratmann, K et al. (1995) Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance. Mol Pharmacol 47:241-7
Zilfou, J T; Smith, C D (1995) Differential interactions of cytochalasins with P-glycoprotein. Oncol Res 7:435-43
Smith, C D; Prinsep, M R; Caplan, F R et al. (1994) Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product. Oncol Res 6:211-8